Innate Pharma SA
F:IDDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innate Pharma SA
F:IDDA
|
FR |
|
E
|
Everfuel A/S
XMUN:0HR
|
DK |
|
Fraser and Neave Ltd
SGX:F99
|
SG |
|
M
|
McChip Resources Inc
XTSX:MCS
|
CA |
|
F
|
Frasers Property (Thailand) PCL
SET:FPT
|
TH |
Wall St Price Targets
IDDA Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for IDDA is 5.24 EUR with a low forecast of 4.36 EUR and a high forecast of 6.25 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IDDA's stock price target?
Price Target
5.24
EUR
According to Wall Street analysts, the average 1-year price target for IDDA is 5.24 EUR with a low forecast of 4.36 EUR and a high forecast of 6.25 EUR.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
1 086%
The compound annual growth rate for Gross Profit over the next 3 years is 1 086%.
